Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems

Author:

Koleva-Kolarova Rositsa1ORCID,Vellekoop Heleen2ORCID,Huygens Simone2ORCID,Versteegh Matthijs2ORCID,Mölken Maureen Rutten-van23ORCID,Szilberhorn László45ORCID,Zelei Tamás4ORCID,Nagy Balázs4ORCID,Wordsworth Sarah16ORCID,Tsiachristas Apostolos16ORCID

Affiliation:

1. Health Economics Research Centre, University of Oxford, Oxford, UK

2. Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

3. Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

4. Syreon Research Institute, Budapest, Hungary

5. Eötvös Loránd University, Budapest, Hungary

6. National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK

Abstract

The cost–effectiveness and budget impact of introducing extended DPYD testing prior to fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The Netherlands and Hungary were examined. DPYD testing with ToxNav© was cost-effective in all three countries. In the UK and The Netherlands, the ToxNav strategy led to more quality-adjusted life years and fewer costs to the health systems compared with no genetic testing and standard dosing of capecitabine/5-fluorouracil. In Hungary, the ToxNav strategy produced more quality-adjusted life years at a higher cost compared with no testing and standard dose. The ToxNav strategy was found to offer budget savings in the UK and in The Netherlands, while in Hungary it resulted in additional budget costs.

Funder

Horizon 2020 Framework Programme

Publisher

Future Medicine Ltd

Subject

Pharmacology,Molecular Medicine,General Medicine

Reference38 articles.

1. Economic burden of cancer across the European Union: a population-based cost analysis

2. National Institute for Health and Care Excellence. Advanced breast cancer: diagnosis and treatment. Clinical guideline CG81 (2009). www.nice.org.uk/guidance/cg81 (Accessed 16 December 2021).

3. Statistics Netherlands (CBS). www.cbs.nl/en-gb (16 December 2021).

4. Breast cancer screening knowledge among Hungarian women: a cross-sectional study

5. International Agency for Research on Cancer. GLOBOCAN 2020. https://gco.iarc.fr/today/data/factsheets/populations/348-hungary-fact-sheets.pdf (16 December 2021).

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3